Citicoline as an Adjunct Therapy in Glaucoma: New Evidence
Two new papers on citicoline as an adjunct therapy in glaucoma landed within about three weeks of each other, and both look at the same question: does citicoline help people with glaucoma? The short answer from both is “maybe, but not proven.” This post walks through what each study found, where the evidence is weak, and what it means for anyone sourcing or developing citicoline-based products.
If you are searching for data on citicoline as an adjunct therapy in glaucoma, here is the honest summary. The signals are interesting, especially in retinal electrophysiology. Eye pressure does not appear to be affected. But the authors of both papers are careful, and neither supports routine clinical use today.
News snapshot (as of November 19, 2026)
- October 27, 2026: a systematic review of 15 studies in Medicines concludes that current evidence does not support routine clinical use of citicoline in glaucoma.
- November 10, 2026 (online October 29): a 12-month, 80-patient Italian cohort study in Frontiers in Neuroscience reports better microperimetric sensitivity with oral citicoline, but its authors call the result an association, not efficacy.
- Common ground: neither study found a meaningful effect on eye pressure, and both reported good tolerability.
This article is for industry and educational purposes only. It is not medical advice. Anyone with glaucoma should speak to their ophthalmologist before taking any supplement or medicine.
Why citicoline is being studied in glaucoma
Standard glaucoma treatment focuses on lowering intraocular pressure (IOP). But some patients keep losing vision even when pressure is controlled. That gap is why researchers look at neuroprotection, meaning approaches that aim to support retinal ganglion cells and the optic nerve directly.
Citicoline has been studied in this context for years. The 2026 systematic review describes neurobiological effects “consistent with neuroprotection,” while stressing that the clinical significance is still uncertain. That distinction matters for everything below.
Study 1: A systematic review of 15 studies (Medicines, October 2026)
A team led by Mendes and colleagues published Citicoline as an Adjunct Therapy in Glaucoma: A Systematic Review of Clinical Outcomes and Safety in Medicines (2026, 13(4), 31), online on October 27, 2026.
What they reviewed
- 15 studies in total: 10 randomized controlled trials and 5 non-randomized trials
- Sample sizes from 11 to 146 participants, mostly open-angle glaucoma
- PRISMA 2020 methods, with a narrative synthesis rather than a pooled meta-analysis
What they found
- Electrophysiology was the most consistent signal. Several studies reported better retinal and post-retinal responses (PERG and VEP measures). Some of those changes reversed after treatment stopped.
- Structure showed some benefit. Two RCTs reported less thinning of the retinal nerve fiber layer and ganglion cell complex in citicoline groups, with stable eye pressure.
- Visual field results were mixed. Some studies reported slower progression of mean deviation, while others found no significant difference.
- Visual acuity and quality of life were inconsistent. Only one study reported a visual acuity improvement, and quality-of-life findings were modest or not significant.
- Safety looked good. Citicoline was generally well tolerated by oral, topical and intramuscular routes, with no serious adverse events reported and no meaningful effect on IOP.
The authors’ conclusion: current evidence does not support routine clinical use, and well-designed randomized trials with standardized, patient-relevant outcomes are needed.
Limitations they flagged
- Designs, doses, routes, durations and outcome measures varied too much to pool
- Small samples and mostly short follow-up
- Only three RCTs were rated low risk of bias, and most non-randomized trials were rated serious or critical risk
- No GRADE certainty assessment was performed
- Formulation differences and combination products may have confounded results
- Publication and selective reporting bias could not be excluded
Study 2: A 12-month oral citicoline cohort in Italy (Frontiers in Neuroscience, November 2026)
The second paper is a prospective cohort study, Oral citicoline as add-on therapy in open-angle glaucoma, published in Frontiers in Neuroscience (volume 20) on November 10, 2026, with an online date of October 29, 2026.
Design
- Single-center, open-label, non-randomized study at the Ophthalmology Unit of the “A. Fiorini” Hospital in Terracina, Italy
- 80 patients with progressing primary open-angle or normal-tension glaucoma, 40 per group
- The treatment group took oral citicoline, 500 mg twice daily. The comparison group declined because of cost and continued conventional therapy alone.
- 12 months of follow-up
Results
- Primary endpoint: microperimetric mean sensitivity changed by +1.7 dB with citicoline versus −0.4 dB in controls (adjusted treatment × time interaction, p < 0.001)
- Fixation stability measures improved only in the citicoline group
- IOP was comparable between groups at 12 months (p = 0.30)
- Secondary outcomes (visual field, RNFL, GCC and OCT angiography vessel density) favored citicoline. The authors state these differences were small, were not corrected for multiple comparisons, and were largely within test–retest variability.
- Responders: 65% in the citicoline group versus 22.5% in controls, using a post hoc definition
- Safety: five patients (12.5%) had mild, transient adverse events, and none stopped treatment
The authors’ own caveat: because patients chose their treatment and assessments were unmasked, the findings “describe an association, not efficacy.” They call for randomized, placebo-controlled trials.
Earlier context: a small randomized trial from late 2025
These two papers follow a small randomized, double-blind trial published online on December 27, 2025 in the Journal of Clinical Medicine (2026, vol. 15, issue 1, article 223). It enrolled 32 patients with open-angle glaucoma, and 29 completed follow-up (15 on citicoline, 14 on placebo). The citicoline group took 500 mg per day as an oral solution for 12 months, alongside their usual beta-blocker therapy.
- Retinal and visual-pathway signals (PERG and VEP) improved in the citicoline group, while the placebo group showed no significant change.
- Visual field mean deviation improved by about 1.8 dB at 12 months with citicoline, while the placebo group declined slightly.
- Diffusion MRI trends were not statistically significant, which the authors link to limited power.
- The authors call the findings preliminary. The sample was small and the study was designed around a VEP primary endpoint.
It fits the same pattern: encouraging functional signals, small studies, and a need for larger trials.
Citicoline as an adjunct therapy in glaucoma: what the two new studies agree on
| Question | Systematic review (Medicines) | Italian cohort (Frontiers) |
|---|---|---|
| Does it lower eye pressure? | No meaningful effect on IOP | IOP comparable between groups |
| Any functional signal? | Most consistent in electrophysiology; visual field mixed | Microperimetric sensitivity improved (+1.7 dB vs −0.4 dB) |
| Is it safe? | Generally well tolerated, no serious adverse events | Mild, transient events in 12.5%; no discontinuations |
| Is the evidence strong enough for routine use? | No | Association, not efficacy |
The pattern is consistent. Citicoline looks tolerable and does not act through eye pressure. Whether it protects vision over the long term is still an open question, and the quality of the existing trials is the main barrier.
How to read the results fairly
A few points help keep the data in proportion:
- A statistically significant result is not the same as a proven benefit. The cohort’s primary endpoint was significant, but the study was not randomized or masked, and the group that declined treatment did so because of cost, which can introduce differences between groups.
- Small changes can sit inside measurement noise. The authors themselves note that several secondary differences were within test–retest variability.
- Post hoc “responder” rates are weaker evidence. The 65% versus 22.5% figure was defined after the fact.
- Different routes and doses are being compared. The review covers oral, topical and intramuscular use at varying doses, which is a major reason the data could not be pooled.
- It was studied as an add-on. Both papers frame citicoline as adjunct therapy alongside conventional treatment, not as a replacement for it.
What this means for manufacturers, formulators and buyers
For the pharmaceutical supply chain, the practical takeaways are straightforward:
- Interest is real but the indication is unproven. Two fresh publications show active research, yet the authors of both call for larger randomized trials. Product plans should not assume a glaucoma indication.
- Formulation and route vary across the literature. Oral, topical and intramuscular use have all been studied. Teams exploring ophthalmic or oral formats should check the specific form and dose used in any study they rely on.
- Documentation and quality matter more as scrutiny grows. When a molecule draws fresh clinical attention, buyers and regulators look harder at specifications, impurity profiles, batch consistency and regulatory filings. A supplier’s quality system and documentation package is a core part of the buying decision.
- Claims discipline is essential. Marketing a citicoline product for glaucoma on the strength of these papers would go beyond what the authors themselves conclude.
If you source citicoline sodium API for pharmaceutical or nutraceutical use, ask any supplier for batch-wise certificates of analysis, GMP status, regulatory documentation available, and stability data before committing.
Frequently asked questions
Does citicoline lower eye pressure in glaucoma?
Not according to the two new studies. The systematic review found no meaningful effect on intraocular pressure, and in the Italian cohort IOP was comparable between the citicoline and control groups at 12 months. Any proposed benefit is therefore not mediated through pressure lowering.
Does the new evidence support using citicoline for glaucoma routinely?
No. The authors of the 2026 systematic review state that current evidence does not support routine clinical use. The cohort study’s authors describe their findings as an association rather than proof of efficacy.
Which routes of citicoline have been studied in glaucoma?
The systematic review covers oral, topical and intramuscular use, and reports good tolerability across all three. The Italian cohort used oral citicoline at 500 mg twice daily.
Is citicoline safe to take alongside glaucoma medicines?
In the studies reviewed, citicoline was generally well tolerated with no serious adverse events, and it had no meaningful effect on IOP. Whether it suits an individual patient is a decision for their ophthalmologist, who should be told about any supplement being taken.
Why are researchers still testing citicoline if results are mixed?
Electrophysiology signals and some structural findings are encouraging, and the safety profile appears favorable. The problem is study quality: small samples, short follow-up, varied designs and risk of bias. Larger randomized, placebo-controlled trials with standardized outcomes are what the field needs.
What should API buyers check before sourcing citicoline sodium?
Ask for a certificate of analysis for each batch, evidence of GMP compliance, the regulatory documents available for your target market, impurity data and stability data. Confirm that the grade offered suits your intended use, whether pharmaceutical or nutraceutical.
Talk to Chemox Pharma about citicoline sodium API
Chemox Pharma is a WHO-GMP certified Citicoline Sodium API manufacturer based in Dahej, Gujarat, supplying pharmaceutical customers worldwide. If you are evaluating citicoline sodium for a pharmaceutical or nutraceutical project, our team can share specifications, documentation and sample details.





